Your browser doesn't support javascript.
loading
Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
Alves de Oliveira Junior, Haliton; Pereira da Veiga, Tiago; Acurcio, Francisco De Assis; Almeida, Alessandra Maciel; Ribeiro Dos Santos, Jessica Barreto; da Silva, Michael Ruberson Ribeiro; Kakehasi, Adriana Maria; Cherchiglia, Mariangela Leal.
Afiliação
  • Alves de Oliveira Junior H; Health Technology Assessment Unit, Hospital Alemão Oswaldo Cruz , São Paulo, Brazil.
  • Pereira da Veiga T; Health Technology Assessment Unit, Hospital Alemão Oswaldo Cruz , São Paulo, Brazil.
  • Acurcio FA; Social Pharmacy Department, Universidade Federal De Minas Gerais , Belo Horizonte, Brazil.
  • Almeida AM; Social Pharmacy Department, Universidade Federal De Minas Gerais , Belo Horizonte, Brazil.
  • Ribeiro Dos Santos JB; Social Pharmacy Department, Universidade Federal De Minas Gerais , Belo Horizonte, Brazil.
  • da Silva MRR; Centro de Ciências Exatas, Naturais e da Saúde, Pharmacy and Nutrition Department, Universidade Federal Do Espírito Santo , Vitória, Brazil.
  • Kakehasi AM; School of Medicine, Universidade Federal De Minas Gerais , Belo Horizonte, Brazil.
  • Cherchiglia ML; School of Medicine, Universidade Federal De Minas Gerais , Belo Horizonte, Brazil.
Hosp Pract (1995) ; 48(4): 213-222, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32567403
OBJECTIVES: To evaluate the association between biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) use and quality of life (QoL) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). PATIENTS AND METHODS: We evaluated adult patients prescribed biological DMARDs whose quality of life was evaluated at six and 12 months. The EuroQol 5 dimensions (EQ-5D) was used with the Brazilian tariff. RESULTS: Patients receiving bDMARDs had significant improvements in quality of life after 6 and 12 months (p < 0.001), regardless of the rheumatic condition and the therapeutic regimen (bDMARDs vs bDMARDs plus synthetic DMARDs) (ANCOVA; p > 0.05). At the end of one year, 62.6% of the participants presented significant clinical improvement in QoL. According to a sensitivity analysis, QoL results in the complete case analysis and in the multiple imputation model yielded similar conclusions. Patients with two or more comorbidities and worse QoL and disability status on baseline presented worse QoL at 12 months when compared to those with better disability status on baseline. Baseline clinical disease measured by activity indexes (BASDAI and CDAI) did not influence QoL after 12 months of bDMARD treatment. Pain and malaise were the EQ-5D domain that most influenced quality of life. CONCLUSION: Patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis displayed significantly better QoL levels following treatment with DMARDs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Doenças Reumáticas / Antirreumáticos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Brasil Idioma: En Revista: Hosp Pract (1995) Assunto da revista: HOSPITAIS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Doenças Reumáticas / Antirreumáticos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Brasil Idioma: En Revista: Hosp Pract (1995) Assunto da revista: HOSPITAIS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido